# Pfizer Licenses Chai AI Platform to Advance Biologics Discovery

> The pharmaceutical company integrates generative models for antibody design, securing early access to Chai-3 and custom training on proprietary data to target previously difficult biologics candidates.

*Published 2026-08-29 · By Samira Reyes*

Pfizer's license agreement with Chai Discovery for its generative AI platform is a deployment of zero-shot antibody design technology for biologics discovery against difficult targets.

## Executive Summary

Pfizer, a leading pharmaceutical company with 2025 revenue of $63 billion, has licensed the Chai Discovery generative AI drug discovery platform for deployment within its research and development operations. The agreement grants access to the Chai-3 model along with a custom model trained on Pfizer's proprietary data and adapted to its internal workflows. This enables in-house zero-shot antibody design capabilities focused on biologics targeting difficult-to-drug candidates.

The core quantified outcome centers on performance metrics from the underlying technology. Chai-2 demonstrated an experimentally validated hit rate of 16 percent, representing a 100-fold increase compared to prior state-of-the-art computational approaches that achieved less than 0.1 percent. Chai-3 further improves on this by doubling the success rate of its predecessor while producing antibodies that meet required therapeutic standards.

For C-suite executives in the pharmaceutical sector, the deployment illustrates a shift from reliance on traditional screening methods toward integrated AI tools that can accelerate early-stage discovery. The in-house nature of the deployment allows Pfizer to retain control over proprietary data and workflows while leveraging frontier generative models.

## Background and Context

Traditional biologics discovery has long depended on high-throughput screening and iterative experimental validation, processes that often yield low hit rates when addressing complex protein targets. These methods require substantial time and resources, with success rates frequently below 0.1 percent in computational predictions before experimental confirmation. Pharmaceutical organizations have sought computational approaches that can narrow the candidate pool more effectively.

Generative AI models have emerged as a potential alternative by learning patterns from large datasets to propose antibody sequences directly. Chai Discovery developed its platform to address limitations in earlier computational tools, focusing on zero-shot design where the model generates candidates without prior examples of the specific target. This approach aligns with enterprise needs for scalable, data-driven discovery pipelines.

Pfizer's decision to license the platform reflects broader industry interest in AI enablement for drug discovery. The company joins other major players exploring similar technologies, though the specific terms and deployment details remain tied to internal validation processes.

## Details of the License Agreement

The license agreement allows Pfizer to deploy Chai's AI platform as part of its drug discovery engine. Key provisions include early access to the previously undisclosed Chai-3 model and the ability to train a custom version on Pfizer's proprietary data. The custom model is tailored to align with Pfizer's existing workflows and data standards.

Financial terms of the agreement were not disclosed. The arrangement emphasizes in-house deployment, enabling Pfizer scientists to use the tools directly rather than relying on external service models. This structure supports integration with internal systems for biologics programs.

The platform targets biologics discovery against difficult-to-drug targets where traditional methods have shown limited success. By providing generative capabilities for antibody design, the deployment aims to expand the range of addressable candidates in Pfizer's pipeline.

## Technical Specifics of the AI Platform

Chai-2 established baseline performance for the platform by achieving double-digit experimental hit rates in zero-shot antibody design. This marked the first instance of such rates in computational approaches for this task. The 16 percent hit rate translated to a 100-fold improvement over previous methods that operated below 0.1 percent.

Chai-3 builds on this foundation with step-change improvements. The model doubles the success rate of Chai-2 and generates antibodies that meet therapeutic standards. Additional performance claims include tighter binding to intended targets, with reports indicating 100 times greater affinity compared to earlier outputs.

Comparison of Antibody Design Performance Metrics Across MethodsMetricTraditional Computational MethodsChai-2Chai-3Hit Rate<0.1%16%Double Chai-2 rateImprovement FactorBaseline100xFurther gains in affinityDesign ApproachIterative screeningZero-shot generativeZero-shot generativeTherapeutic StandardVariableExperimental validationMeets required standards

The zero-shot capability reduces dependence on large experimental datasets for each new target. This technical feature supports faster iteration in early discovery stages while maintaining focus on candidates likely to meet downstream criteria.

## Market and Stakeholder Implications

The agreement signals growing enterprise adoption of generative AI tools in pharmaceutical research and development. For peer companies, the move highlights the potential to augment internal capabilities with licensed frontier models rather than building equivalent systems from scratch.

Stakeholders including investors and regulators may view such deployments as indicators of shifting R&D productivity. The emphasis on proprietary data training addresses concerns around data security and competitive advantage in the sector.

Broader market implications include potential acceleration of biologics programs across the industry. Organizations evaluating similar platforms can reference the Pfizer deployment as a benchmark for integration approaches.

- Assess internal data readiness for custom model training before licensing decisions.
- Evaluate integration requirements with existing discovery workflows and IT infrastructure.
- Define success metrics aligned with experimental validation rates rather than solely computational predictions.
- Monitor regulatory guidance on AI use in drug development for compliance planning.
- Consider phased rollout starting with specific target classes to measure incremental gains.

## Expert Reactions

Joshua Meier, co-founder of Chai Discovery, addressed the partnership in statements tied to the announcement. His comments focused on the direct deployment of the software within a major drug discovery organization.

> Our work with Pfizer is about putting Chai’s software directly into the hands of one of the world’s leading drug discovery organizations.Joshua Meier, co-founder of Chai Discovery

Meier also noted the combination of the AI platform with Pfizer's scientific depth and data resources. This perspective underscores the collaborative aspect of the deployment for expanding biologics discovery possibilities.

> By combining Chai's frontier AI platform with Pfizer's scientific depth, data and discovery capabilities, we see an opportunity to expand and accelerate what is possible in biologics discovery and help Pfizer pursue targets that traditional methods have struggled to reach.Joshua Meier, co-founder of Chai Discovery

## What's Next

Pfizer's deployment of the platform positions the company to generate and test antibody candidates internally using the updated models. Future outcomes will depend on experimental validation results from programs utilizing Chai-3 and the custom variant.

Industry observers anticipate additional partnerships or expansions as other pharmaceutical firms evaluate similar generative AI tools. The undisclosed financial terms leave room for interpretation regarding the scale of investment required for comparable deployments.

Continued model development by Chai Discovery may yield further iterations beyond Chai-3, potentially influencing how enterprises structure ongoing license agreements. The focus remains on measurable improvements in discovery efficiency and target coverage.

## Sources

1. [The agreement will enable Pfizer to deploy Chai’s AI platform as part of its drug discovery engine, gaining early access to the Chai-3 model as well as a custom model that leverages Pfizer's proprietary data and is tailored to Pfizer’s workflows. Chai-3 shows step-change improvements in AI-driven antibody design, doubling the success rate of its predecessor and producing antibodies that meet required therapeutic standards.](https://www.businesswire.com/news/home/20260602498831/en/Chai-Discovery-Announces-License-Agreement-with-Pfizer-to-Accelerate-Drug-Discovery-with-AI)
2. [It was Chai-3 that convinced Pfizer to sign on. The model doubles the success rate of the startup’s previous model and produces antibodies that bind 100 times more tightly to their intended therapeutics targets, according to the company.](https://www.forbes.com/sites/amyfeldman/2026/06/04/why-pfizer-and-eli-lilly-are-betting-on-this-13-billion-ai-drug-discovery-startup/)
3. [Chai-2 achieved an experimentally validated antibody design hit rate of 16%, representing a 100x increase over prior state-of-the-art hit rates of less than 0.1%.](https://chai-discovery.gitbook.io/talent)
4. [By combining Chai's frontier AI platform with Pfizer's scientific depth, data and discovery capabilities, we see an opportunity to expand and accelerate what is possible in biologics discovery and help Pfizer pursue…](https://pharmexec.com/view/chai-discovery-license-agreement-pfizer-accelerate-drug-discovery-with-ai)

---
Source: https://aiintelreport.com/enterprise-ai/pfizer-chai-ai-biologics-discovery
Index: https://aiintelreport.com/llms.txt · Full text: https://aiintelreport.com/llms-full.txt